S3指南:表皮坏死松解症(Stevens-Johnson综合征与中毒性表皮坏死松解症)诊断与治疗——第2部分:EN急性期与急性期后支持治疗
表皮坏死松解症(EN)包括Stevens-Johnson综合征与中毒性表皮坏死松解症,是罕见、主要为药物诱发的急性危及生命的皮肤黏膜疾病,发病率与死亡率高、疾病负担重。该指南由德国科学医学学会协会(AWMF)规定,在系统考虑现有科学文献并经过正式共识过程后制定,旨在建立循证框架支持临床决策。指南委员会由多个专科协会代表与患者代表组成,面向皮肤科、眼科、整形外科、重症医学与儿科等专科医师,以及患者、家属、保险机构与政策制定者。第2部分涉及EN急性期支持治疗与门诊随访治疗。
要点
- SJS/TEN现被视为同一疾病实体——表皮坏死松解症(EN)的不同严重程度变异型。
- EN罕见、主要为药物诱发、急性危及生命,累及皮肤与黏膜,发病率与死亡率高。
- 该S3指南按AWMF规定经正式共识过程制定,系统考虑现有科学文献,建立循证框架支持临床决策。
- 指南面向皮肤科、眼科、整形外科、重症医学与儿科等专科医师,以及患者、家属、保险机构与政策制定者。
- 第2部分聚焦EN急性期支持治疗与门诊随访治疗。
适用人群与场景
- 适用于皮肤科、眼科、整形外科、重症医学与儿科等在医院和诊所的专科医师,以及其他参与EN诊断与治疗的专业人员。
- 也面向患者、其家属、保险基金与政策制定者。
研究设计与关键结果
- 指南由德国科学医学学会协会(AWMF)规定,在系统考虑现有科学文献并经过正式共识过程后制定,旨在建立循证框架支持临床决策。
- 指南委员会由多个专科协会代表与患者代表组成,为跨学科指南委员会。
- 第2部分涉及EN急性期支持治疗与门诊随访治疗。
证据类型、等级与局限
- 证据类型:S3指南(德国科学医学学会协会AWMF)。
- 制定方法:系统考虑现有科学文献,按AWMF规定经正式共识过程制定。
- 局限:原文未报告局限性
指南或共识出处
- 指南名称:S3指南:表皮坏死松解症(Stevens-Johnson综合征与中毒性表皮坏死松解症)诊断与治疗——第2部分:EN急性期与急性期后支持治疗。
- 发布机构:德国科学医学学会协会(AWMF)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered as variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline "Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)" was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and of patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical specialties involved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. The second part is concerned with the topics of supportive therapy in the acute phase of EN and outpatient follow-up treatment.
参考来源
- Paulmann M, Heuer R, Annecke T, et al. S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 2: Supportive therapy of EN in the acute and post-acute stages. J Dtsch Dermatol Ges. 2024. PMID: 39417754. doi:10.1111/ddg.15516
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。